Why Are Many Women At Risk of Ovarian Cancer Not Aware Of It?

November 2, 2015 11:00 am

The statistics for ovarian cancer are frightening. Whereas early detection tests for breast cancer are relatively commonplace, 75-85% of women with ovarian cancer are diagnosed only at a late stage, when the cancer has spread and prognosis is poor.

More … Read more

Effective Ovarian Cancer Treatment Is Underused, Study Finds

October 30, 2015 11:00 am

Deborah Denehy received chemotherapy directly to her abdomen to treat ovarian cancer, a treatment that remains underused in the United States. Credit Shiho Fukada for The New York Times.

In 2006, the National Cancer Institute took the rare step … Read more

Liz Laats Shares Her Story at Clearity’s Glitter and Glue for Good

October 27, 2015 11:00 am

Check out Liz Laats’ amazing speech at Glitter and Glue for Good, not a dry eye in the house.

Thank you to everyone who joined us on March 7th for the inaugaural Glitter & Glue for Good event. More than … Read more

Molecular Profiling of Epithelial Ovarian Cancer

October 24, 2015 11:00 am

Epithelial ovarian cancer (EOC) is the most common cause of gynecological cancer death in the United States, with an estimated 21,290 new cases and 14,180 deaths estimated for 2015 (ACS 2015). The vast majority of women are diagnosed with advanced … Read more

Heart Drug Linked to Extra Years for Cancer Patients

October 20, 2015 11:00 am

A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.

Researchers analyzing a database … Read more

A Heart to Heart Community for Ovarian Cancer Survivors

October 17, 2015 11:00 am

Welcome to my Heart to Heart blog designed in the Clearity Portal to provide ovarian cancer survivors with a “cozy space” where we know we will be welcomed and supported.

I’ve been an ovarian cancer survivor for 7 years. I’ve … Read more

Novel Clinical Trial Designs Match Drugs to Patient’s Tumor Profiles

September 1, 2014 8:07 pm

By: Cory Bentley, PhD

Bringing new treatments to ovarian cancer patients is very challenging.  There are not as many patients diagnosed with this cancer as there are with other cancer types, such as breast, lung and colorectal, so there are … Read more

Eligibility Criteria in Clinical Trials: PARP Inhibitors

July 1, 2013 7:59 pm

By: Cory Bentley, PhD

Clearity first reported on drugs inhibiting PARP (Poly-ADP ribose polymerase), an important enzyme for tumor cell proliferation and survival, in its September 2010 patient newsletter.  At that time, PARP inhibitors were just entering clinical trials and

Read more

CA125 Becomes a Target for Destruction of Ovarian Cancer by Phase I Drug

May 1, 2013 7:50 pm

By: Cory Bentley, PhD

Most ovarian cancer patients have become familiar with CA125 blood level monitoring, but trial drug DMUC5754A from Genentech puts a new twist on this familiar blood marker of advanced ovarian cancer. CA125 (cancer antigen 125) also … Read more

Clinical Trials for Ovarian Cancer Patients: Why Now?

February 1, 2013 7:44 pm

By: Cory Bentley, PhD & Teresa Gallagher, PhD

Ovarian cancer is a very diverse disease on the molecular level. Different tumors have different key molecular players and potentially different Achilles’ heels. Researchers are making real progress in pinpointing key players … Read more